In this study, we evaluated the effectiveness of the specific MD2 inhibitor 21, L6H21, in reducing inflammatory liver injury in a HFD mouse model of NASH and in the PA‐stimulated human liver cell line. The gene discussed is LY96; the disease is metabolic dysfunction-associated steatohepatitis.